| 000 | 01721 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515035853.0 | ||
| 264 | 0 | _c20070222 | |
| 008 | 200702s 0 0 eng d | ||
| 022 | _a0014-2972 | ||
| 024 | 7 |
_a10.1111/j.1365-2362.2006.01685.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSitbon, O | |
| 245 | 0 | 0 |
_aBosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical investigation _cSep 2006 |
||
| 300 |
_a25-31 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aBosentan |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aExercise Test _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Defects, Congenital _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension, Pulmonary _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProstaglandins, Synthetic _xtherapeutic use |
| 650 | 0 | 4 |
_aPulmonary Circulation _xdrug effects |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aSulfonamides _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Resistance _xdrug effects |
| 650 | 0 | 4 |
_aWalking _xphysiology |
| 700 | 1 | _aBeghetti, M | |
| 700 | 1 | _aPetit, J | |
| 700 | 1 | _aIserin, L | |
| 700 | 1 | _aHumbert, M | |
| 700 | 1 | _aGressin, V | |
| 700 | 1 | _aSimonneau, G | |
| 773 | 0 |
_tEuropean journal of clinical investigation _gvol. 36 Suppl 3 _gp. 25-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2362.2006.01685.x _zAvailable from publisher's website |
| 999 |
_c16505540 _d16505540 |
||